• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

FASEB J . SARS-CoV-2 Nucleocapsid Protein Does Not Induce Inflammation in Endothelial Cells or Monocytes

tetano

Editor, Senior Moderator
FASEB J


. 2025 Oct 31;39(20):e71142.
doi: 10.1096/fj.202501433R. SARS-CoV-2 Nucleocapsid Protein Does Not Induce Inflammation in Endothelial Cells or Monocytes

Mehreen Tufail[SUP] 1 [/SUP], Xiangru Lu[SUP] 1 [/SUP], Stephen D Barr[SUP] 2 [/SUP], Nica Borradaile[SUP] 1 [/SUP], Qingping Feng[SUP] 1 [/SUP]



Affiliations
Abstract

The nucleocapsid (N) protein of SARS-CoV-2 is critical for viral replication and genome packaging. However, whether it induces inflammation through endothelial cell and monocyte activation remains controversial. One aspect that has been overlooked is the consideration of residual endotoxins in recombinant proteins when conducting immune response studies. We aimed to assess whether N-protein induces an inflammatory response in mouse and human microvascular endothelial cells (MEC and HMEC) and THP-1 cells, independent of endotoxin contamination. MEC, HMEC, and THP-1 cells were treated with vehicle, lipopolysaccharide (LPS), or recombinant N-protein in the presence or absence of the LPS-neutralizing agent polymyxin B. The inflammatory response was assessed through quantification of mRNA and protein levels of inflammatory markers and monocyte adhesion to endothelial cells. In MEC, treatment with N-protein resulted in at least a 15-fold increase in inflammatory marker levels. Similarly, in THP-1 cells, N-protein caused a significant increase in mRNA inflammatory marker levels, which were brought back to control levels with polymyxin B. LPS or N-protein alone resulted in a tripling of monocyte adhesion to MEC, and this was reduced to control levels with polymyxin B. In addition, in HMEC, endotoxin-depleted N-protein did not cause a significant increase in inflammatory marker levels. In conclusion, our data show that N-protein does not induce inflammation in endothelial cells or monocytes. Some of its observed inflammatory effects may be due to endotoxin contamination, suggesting that it does not directly induce inflammation.

Keywords: COVID‐19; endothelial cells; endotoxin contamination; inflammation; monocytes; nucleocapsid protein.

 
Back
Top